Bevacizumab found to be Effective for diabetic macular oedem
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
This study evaluated the 1-year treatment outcomes of bevacizumab for diabetic macular oedema (DMO) in routine clinical practice which was found to be effective amongst the patients.

A retrospective analysis was performed on 298 eyes of 220 patients with DMO that received intra-vitreal bevacizumab.

--The mean visual acuity at 1-year was 3 (2, 5) letters better than a mean (SD) of 68 letters at study entry.

--Nearly a quarter of eyes achieved more than 20/40. Eyes presenting with better vision (more than 20/40) tended to maintain that vision during the period of observation, whereas those presenting with worse vision (less than 20/40) gained a mean of 9 (5, 13) letters.

--A mean reduction in the macular thickness was observed over the study period with the central subfield improving by 29?microm from a mean (SD) of 402 µm at study entry.

--Eyes that completed 1 year of follow-up received a median (Q1, Q3) of 7 bevacizumab injections. 62 eyes, that started with bevacizumab changed to either another VEGF inhibitor or steroid (triamcinolone) during the period of observation.

--This did not lead to functional improvement for eyes changed to either ranibizumab or aflibercept despite a further reduction in macular thickness.

--An improvement in vision and reduction in macular thickness was noted in the 13 eyes that subsequently received triamcinolone.

--Approximately 10% of eyes dropped out over 12 months, even though their mean visual acuity had improved by 7 letters from the initial visit.

Conclusively, Bevacizumab is an effective treatment for DMO in unselected populations.